Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is -32.81% as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly return on assets; no daily interpolation.
Limited quarterly history available
ROA needs at least three reported quarters before a meaningful chart is shown.
RETURN ON ASSETS (ROA)
-32.81%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 789 covered companies
CURRENT VS SECTOR MEDIAN
-4.59%
vs the sector median at left
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.34B
Return on Assets (ROA)
-32.81%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.34B
Return on Assets (ROA)
43.52%
TTM Avg
-28.82%
3Y Avg
-20.19%
5Y Avg
-30.60%
Market Cap
$1.32B
Return on Assets (ROA)
-68.96%
TTM Avg
-38.41%
3Y Avg
-33.02%
5Y Avg
-35.57%
Market Cap
$1.40B
Return on Assets (ROA)
-89.60%
TTM Avg
418.97%
3Y Avg
177.41%
5Y Avg
100.38%
Market Cap
$1.41B
Return on Assets (ROA)
-21.52%
TTM Avg
-21.52%
3Y Avg
-21.52%
5Y Avg
-21.52%
Market Cap
$1.27B
Return on Assets (ROA)
-49.10%
TTM Avg
-49.10%
3Y Avg
-49.10%
5Y Avg
-49.10%
Market Cap
$1.42B
Return on Assets (ROA)
3.12%
TTM Avg
3.19%
3Y Avg
2.54%
5Y Avg
2.30%
Market Cap
$1.41B
Return on Assets (ROA)
61.75%
TTM Avg
-16.82%
3Y Avg
-22.73%
5Y Avg
-17.45%
Market Cap
$1.44B
Return on Assets (ROA)
-25.13%
TTM Avg
-5.66%
3Y Avg
-57.10%
5Y Avg
-57.10%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.34B | -32.81% | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | 43.52% | -28.82% | -20.19% | -30.60% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | -68.96% | -38.41% | -33.02% | -35.57% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | -89.60% | 418.97% | 177.41% | 100.38% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | -21.52% | -21.52% | -21.52% | -21.52% |
| Kardigan, Inc. (KARD)vs › | $1.27B | -49.10% | -49.10% | -49.10% | -49.10% |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 3.12% | 3.19% | 2.54% | 2.30% |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 61.75% | -16.82% | -22.73% | -17.45% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | -25.13% | -5.66% | -57.10% | -57.10% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | -46.39% | -37.70% | -40.46% | -33.71% |
ROA
-32.8%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -32.81% |
